title: Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in postmenopausal women.
abstract: OBJECTIVE
  This study investigated the effect of estrogen on brain serotonin 2A (5-HT(2A)) receptors in postmenopausal women and whether there was any correlation of receptor changes with cognition and mood.
  
  
  METHODS
  Ten postmenopausal subjects underwent positron emission tomography measurements of 5-HT(2A) receptor binding with [(18)F]deuteroaltanserin before and after estrogen replacement therapy.
  
  
  RESULTS
  5-HT(2A) receptor binding was significantly increased after estrogen replacement therapy in the right prefrontal cortex (right precentral gyrus [Brodmann's area 9], inferior frontal gyrus [Brodmann's area 47], medial frontal gyrus [Brodmann's area 6, 10] and the anterior cingulate cortex [Brodmann's area 32]). In the inferior frontal gyrus [Brodmann's area 44]), receptor up-regulation was correlated with change in plasma estradiol. Verbal fluency and Trail Making Test performance, but not mood, were significantly improved by estrogen without correlation with receptor changes.
  
  
  CONCLUSIONS
  Estrogen increases 5-HT(2A) receptor binding in human prefrontal regions.
authors.affiliation: Department of Psychiatry, Yale University, New Haven, Conn 06516, USA. akira@kugaya@yale.edu
authors.forename: Akira
authors.initials: A
authors.lastname: Kugaya
authors.forename: C Neill
authors.initials: CN
authors.lastname: Epperson
authors.forename: Sami
authors.initials: S
authors.lastname: Zoghbi
authors.forename: Christopher H
authors.initials: CH
authors.lastname: van Dyck
authors.forename: Yankun
authors.initials: Y
authors.lastname: Hou
authors.forename: Masahiro
authors.initials: M
authors.lastname: Fujita
authors.forename: Julie K
authors.initials: JK
authors.lastname: Staley
authors.forename: Pradeep K
authors.initials: PK
authors.lastname: Garg
authors.forename: John P
authors.initials: JP
authors.lastname: Seibyl
authors.forename: Robert B
authors.initials: RB
authors.lastname: Innis
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D000368:Aged; D004958:Estradiol / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D015914:Estrogen Replacement Therapy; D005260:Female; D005462:Fluorine Radioisotopes; D005500:Follow-Up Studies; D006801:Humans; D007650:Ketanserin / Q000031:analogs & derivatives*; D008875:Middle Aged; D009483:Neuropsychological Tests; D017698:Postmenopause / Q000187:drug effects / Q000523:psychology*; D017397:Prefrontal Cortex / Q000737:chemistry / Q000000981:diagnostic imaging / Q000378:metabolism*; D011597:Psychomotor Performance; D017966:Pyramidal Cells / Q000737:chemistry / Q000000981:diagnostic imaging / Q000378:metabolism; D044402:Receptor, Serotonin, 5-HT2A; D011985:Receptors, Serotonin / Q000032:analysis / Q000187:drug effects / Q000378:metabolism*; D014055:Tomography, Emission-Computed; D016896:Treatment Outcome
chemical_list: D005462:Fluorine Radioisotopes; D044402:Receptor, Serotonin, 5-HT2A; D011985:Receptors, Serotonin; D004958:Estradiol; C071983:altanserin; D007650:Ketanserin